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188Objective: Leukocytes in allogeneic blood transfusions cause several immunomodulatory events. This before-
and-after cohort study evaluated clinical outcomes after adoption of prestorage leukoreduction program for blood
transfusions, with particular focus on acute kidney injury.
Methods: One thousand thirty-four consecutive patients who underwent on-pump coronary artery bypass grafting
between January 2004 and December 2007 were included. Propensity score analysis for transfusion was performed
in the whole population; patients whowere actually transfusedwere then divided according to leukoreduction. From
these 2 groups, 147 pairs matched for propensity score were considered to evaluate with bivariate and multivariable
analyses the effects of leukoreduction, with all-cause in-hospital mortality and morbidity as main outcomes.
Results: Unadjusted in-hospital mortalities were 6.6% for the entire cohort and 44.2% for those with acute kid-
ney injury. In the matched population, after introduction of leukoreduction, mortality rates decreased to 5.4%
(vs 11.4%) and acute kidney injury (RIFLE [Risk, Injury, Failure, Loss of function, End-stage renal disease] class
R or greater) dropped from 51.7% to 41.5% (relative risk20%, P< .045). No difference emerged regarding
other major complications. At multivariable analysis, intra-aortic balloon pump, RIFLE score, and propensity
score for transfusion proved independent predictors of in-hospital mortality. Intra-aortic balloon pump and non-
leukodepleted transfusion emerged as independent predictors of acute kidney injury. Multivariable analysis on
the overall cohort of transfused patients confirmed that nonleukodepleted transfusion was an independent predic-
tor of acute kidney injury.
Conclusions: Leukoreduction of allogeneic blood products is associated with decreased acute kidney injury and
mortality in highly transfused patients. (J Thorac Cardiovasc Surg 2010;140:188-95)Although allogeneic blood transfusions are commonly used
in supportive care of cardiac surgical patients, they may be
a double-edged sword. In addition to a lifesaving effect
in hemorrhagic shock, transfusion of allogeneic packed
red blood cells (RBCs) can be beneficial in situations of
oxygen-supply dependency to avoid a critically low hemat-
ocrit. These benefits are countered by the risks of
transfusion-associated lung injury, transfusion-associated
immunomodulation, and cellular hypoxia, along with other
well-known drawbacks.1 Numerous studies have been
performed to evaluate the impact of leukoreduction.2 This
possibility was suggested on the basis of studies evaluating
the benefits obtained from white blood cell removal with
specialized filters in reducing the unwanted effects of car-
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The Journal of Thoracic and Cardiovascular Surgshort-term postoperative mortality after transfusions con-
taining allogeneic leukocytes relative to transfusions of
blood leukoreduced by filtration. The precise mechanism
behind such a survival benefit remains uncertain. No au-
thoritative meta-analysis has yet provided convincing evi-
dence for or against implementation of universal white
blood cell reduction in this surgical setting.2 Recently, an
article by Blumberg and colleagues4 questioned the validity
of such a meta-analysis because it did not investigate med-
ical sources of heterogeneity (intention to treat, as treated)
and did not include the most recent randomized, controlled
trials.
As part of our hospital’s ongoing continuous quality im-
provement program, we performed a prospective cohort
study designed to survey blood transfusion practice and its
effects on outcomes in cardiac surgery. The relative database
was later used to determine the impact of a universal leukor-
eduction program on hospital mortality and morbidity
among patients referred for coronary artery bypass grafting
(CABG) in a tertiary care, university-affiliated center.
MATERIALS AND METHODS
Study Setting and Patient Sample
The studywas conducted at the Department of Cardiothoracic and Respi-
ratory Sciences of the Second University of Naples, located in an affiliatedery c July 2010
Abbreviations and Acronyms
CABG ¼ coronary artery bypass grafting
CSA-
AKI
¼ cardiac surgery–associated acute kidney
injury
GFR ¼ glomerular filtration rate
IABP ¼ intra-aortic balloon pump
RBC ¼ red blood cell
RIFLE ¼ Risk, Injury, Failure, Loss of function,
End-stage renal disease
Romano et al Perioperative Managementteaching hospital (V. Monaldi Hospital). At our institution, nearly 700
patients undergoing cardiac surgery annually are admitted to a dedicated
12-bed postoperative intensive care unit. Information from these patients
is collected on a daily basis with standardized case report forms; all clinical
perioperative data (including demographic data, laboratory tests, nature of
surgery, blood product transfusions, reexploration, postoperative complica-
tions, and stays in the intensive care unit and the hospital) are collected. Data
are entered into a computerized database that includes 100 variables and is
programmed to accept only matching double-entry data falling within pre-
specified ranges. All queries are resolved by referring to the patients’ orig-
inal records. Of 1323 consecutive patients undergoing CABG between
January 2004 and December 2007, a total of 1034 patients without preoper-
ative transfusions who underwent on-pump procedures and survived longer
than 24 hours after the completion of the index surgical procedure consti-
tuted the study sample.
Universal prestorage leukoreduction was implemented in our hospital
starting from January 2006, fulfilling the European and German standard
for leukoreduced blood products of less than 1 3 106 residual white blood
cells. A total of 563 patients were enrolled during the control period, and
471 patients were enrolled after the advent of prestorage leukoreduction.Study Design and Aims
In this before-and-after retrospective cohort study, the influence of leu-
kodepletion on in-hospital mortality and morbidity was investigated in con-
secutive patients undergoing CABG. Research protocol was approved by
the local ethics and research committee, which waived the need for informed
consent.P
MSurgical and Clinical Care
All procedures were performed by the same 3 senior surgeons (G.N.,
M.C., M.S.) throughout the study period. Details on surgical strategy and
postoperative care have been reported extensively elsewhere.5,6 Aprotinin
was never used for bleeding prevention, because it is not authorized in
our country; tranexamic acid was given preoperatively to patients
receiving dual antiplatelet therapy. Heparinization was managed by
monitoring both heparin blood level and activated coagulation time. An
intraoperative autologous blood salvage method was used for every
patient with preoperative anemia. A specific perioperative transfusion
algorithm was applied: patients received 2 units of packed RBCs before
cardiopulmonary bypass whenever the preoperative hematocrit value was
below 30%, and they received 2 or more units of packed RBCs during
cardiopulmonary bypass in cases of excessive hemodilution (hematocrit
<22%). After cardiopulmonary bypass, the patients received packed
RBCs to maintain a hematocrit value higher than 25%. This target value
was raised to a higher value according to the clinical condition, the
hemodynamic status, the need for inotropic support, and the age of the
patient. Fresh-frozen plasma was not used before the patient reached the in-
tensive care unit. Platelets were usually not transfused, except for patientsThe Journal of Thoracic and Cawho reached the operating room with a full dose of ticlopidine or clopidog-
rel and had severe postoperative bleeding. Such a protocol complies with
recently published guidelines.7
Baseline Data and Clinical Outcomes
All definitions were established as part of the original study design.
Incidence of cardiac surgery–associated acute kidney injury (CSA-AKI) ac-
cording to RIFLE (Risk, Injury, Failure, Loss of function, End-stage renal
disease) criteria was investigated.8 The change in kidney function was based
on plasma creatinine concentration and defined as the difference between
baseline concentration and the highest concentration during the stay in the
intensive care unit.
Preoperative glomerular filtration rate (GFR) and nadir GFR during in-
tensive care unit stay were calculated with the Modification of Diet in Renal
Disease equation: estimated GFR ¼ 186 3 (plasma creatinine level in mg/
dL)1.1543 (age in years)0.203. For women, the product of this equation was
multiplied by a correction factor of 0.742.9 The classification for acute kid-
ney injury by the Acute Dialysis Quality Initiative Workgroup was con-
structed. This classification is named RIFLE for its grades of severity of
renal impairment. The standard defines 3 grades of severity—risk (class
R), injury (class I), and failure (class F)—and 2 outcome classes—loss of
kidney function (class L) and end-stage renal disease (class E). This classi-
fication system includes separate criteria for creatinine and urinary output. A
patient can fulfill the criteria through changes in serum creatinine, estimated
GFR, or urinary output, with the criterion that leads to the worst possible
classification being used. Class R is considered if there is a 1.5-fold increase
in serum creatinine, a GFR decrease greater than 25%, or a urinary output
less than 0.5 mL/(kg $ h) for 6 hours; class I is considered if there is a 2-fold
increase in serum creatinine, a GFR decrease greater than 50%, or a urinary
output less than 0.5 mL/(kg $ h) for 12 hours; and class F is considered if
there is a 3-fold increase in serum creatinine, a GFR decrease greater than
75%, a serum creatinine greater than 4 mg/dL in conjunction with an acute
rise in serum creatinine of at least 0.5 mg/dL, a urinary output less than
0.3 mL/(kg $ h) for 24 hours, or anuria for 12 hours. The main parameters
considered in this study for CSA-AKI definition were creatinine and GFR
because of the heterogeneity of volemic status and diuretic use among the
study patients, which obscured the relationship between renal status and uri-
nary output.
Cardiac morbidity was defined as the occurrence of myocardial infarc-
tion or heart failure. The diagnosis of myocardial infarction required either
the development of new Q waves, new and persistent ST-segment or
T-wave changes associated with an elevation of creatine kinase MB isoen-
zyme values, or autopsy evidence of acute myocardial infarction. The diag-
nosis of heart failure required either the use of a ventricular assist device or
the use of continuous inotropic support for at least 24 hours. Intra-aortic bal-
loon pump (IABP) use was considered as a variable in itself, rather than as
a criterion for heart failure definition, because IABPs were also implanted in
cases of refractory angina or high-risk arrhythmias without pump deficit.
Mediastinitis, bloodstream infection, and pneumonia were defined accord-
ing to Centers for Disease Control and Prevention criteria.6 Respiratory
complications were defined as mechanical ventilation longer than 48 hours
or need for tracheotomy. Fatality (in-hospital mortality) was defined as any
death occurring after surgery and during the index hospitalization.
Statistical Analysis
Data analysis first addressed dissimilarities in clinical profile and course
of patients transfused and not transfused, so that comparison would be fair
and based on more extensive risk adjustment than has been done so far
(Table 1). Bivariate analysis (with the c2 statistic for categoric variables
and the t test and Wilcoxon rank-sum test for continuous variables) was
used to identify significant preoperative, intraoperative, and postoperative
factors associated with transfusion requirements in the general surgical pop-
ulation, with a dichotomous variable reflecting the prevalence of transfused
patients used as a dependent variable. Variables that were not linearlyrdiovascular Surgery c Volume 140, Number 1 189
TABLE 1. Clinical overview of population undergoing isolated coronary artery bypass grafting and at risk for blood transfusion
Total Not transfused Transfused P value
No. of patients 1034 (100%) 563 (54.4%) 471 (45.6%)
Age (y, mean  SD) 63.2  9.4 60.9  8.7 65.9  9.3 <.001
Female (no.) 193 (18.7%) 51 (9.1%) 142 (30.1%) <.001
Body surface area (m2, mean  SD) 1.84  0.16 1.89  0.15 1.78  0.15 <.001
Diabetes (no.) 316 (30.6%) 169 (30%) 147 (31.2%) .538
Hypertension (no.) 724 (70.0%) 394 (70.0%) 330 (70.1%) .977
Hypercholesterolemia (no.) 429 (41.5%) 234 (41.6%) 195 (41.4%) .656
Chronic obstructive pulmonary disease 139 (13.4%) 71 (12.6%) 68 (14.4%) .391
Preoperative glomerular filtration rate (mL/min, mean  SD) 80.1  22.4 84.2  21.3 75.2  22.7 <.001
Chronic renal disease (no.) 39 (3.8%) 13 (2.3%) 26 (5.5%) .048
Ejection fraction #35% (no.) 158 (15.3%) 75 (13.3%) 83 (17.6%) .034
Hematologic disorder (no.) 16 (1.5%) 5 (0.9%) 11 (2.3%) .520
History of hemorrhagic gastropathy (no.) 71 (6.9%) 38 (6.7%) 33 (7.0%) .844
Preoperative anemia (hemoglobin<12 g/dL, no.) 314 (30.4%) 91 (16.2%) 223 (47.3%) <.001
Preoperative hemoglobin (g/dL, mean  SD) 13.4  1.7 14.1  1.3 12.6  1.8 <.001
Use of warfarin (no.) 7 (0.7%) 2 (0.4%) 5 (1.1%) .255
Use of ticlopidine (no.) 46 (4.5%) 18 (3.2%) 28 (6.0%) .023
Use of clopidogrel (no.) 148 (14.4%) 76 (13.5%) 72 (15.4%) .396
Use of aspirin (no.) 468 (45.4%) 253 (45.0%) 215 (45.9%) .767
Urgent or emergency setting (no.) 326 (31.6%) 140 (24.8%) 186 (39.5%) <.001
Resternotomy (no.) 10 (1.0%) 5 (0.9%) 5 (1.1%) >.999
No. of distal anastomoses (mean  SD) 2.66  0.85 2.58  0.86 2.76  0.80 <.001
Pump time (min, mean  SD) 83.5  33.1 77.0  27.5 91.3  37.4 <.001
Aortic crossclamp time (min, mean  SD) 44.8  20.2 42.1  18.1 48.1  22 <.001
Indexed pump flow (L/[m2 min], mean  SD) 2.37  0.20 2.37  0.23 2.38  0.17 .480
Lowest hemoglobin on pump (g/dL, mean  SD) 8.83  1.31 9.4  1.10 8.13  1.20 <.001
Lowest oxygen delivery on pump (mean  SD) 297  49 315  47 276  43 <.001
Blood loss in first 24 h (mL, mean  SD) 715  350 658  266 784  418 <.001
Resternotomy for bleeding (no.) 24 (2.3%) 0 (0%) 24 (5.1%) <.001
Respiratory complication 34 (3.3%) 7 (1.2%) 27 (5.7%) <.001
Intra-aortic balloon pump (no.) 87 (8.4%) 18 (3.2%) 69 (14.6%) <.001
Cardiac complication (no.) 70 (6.8%) 16 (2.8%) 54 (11.5%) <.001
Cerebral complication (no.) 20 (1.9%) 15 (3.2%) 5 (0.9%) .007
RIFLE class R or worse (no.) 391 (37.8%) 183 (32.5%) 208 (44.2%) <.001
Use of continuous venovenous hemofiltration (no.) 34 (3.3%) 2 (0.4%) 32 (6.8%) <.001
Pneumonia (no.) 54 (5.2%) 20 (3.6%) 34 (7.2%) .031
Bloodstream infection (no.) 28 (2.7%) 8 (1.4%) 20 (4.2%) .002
Mediastinitis (no.) 21 (2.0%) 8 (1.4%) 13 (2.8%) .100
Intensive care unit stay (d, mean  SD) 3.3  4.0 2.5  1.4 4.2  5.6 <.001
Hospital stay (d, mean  SD) 8.1  4.8 7.2  2.5 9.2  6.4 <.001
In-hospital mortality (no.) 32 (3.1%) 1 (0.2%) 31 (6.6%) <.001
Red blood cells transfused (units, mean  SD)
Total 1.98  2.74
On pump 0.53  1.03
In operating room 0.77  1.37
In intensive care unit 1.03  1.85
Total fresh plasma transfused (units, mean  SD) 1.49  3.1
Total platelets transfused (units, mean  SD) 1.58  3.9
RIFLE, Risk, Injury, Failure, Loss of function, End-stage renal disease.
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Mrelated were mathematically transformed, categorized along appropriate cut
points, or converted into multiple dichotomous variables. A propensity
score for the likelihood of receiving RBC transfusion was calculated for
each patient with multivariable discriminant analysis by single-step entry
method. All significant variables at bivariate analysis (P  .05) were in-
cluded in the model. The C statistic for such a propensity model was
0.80. With the aim of preventing indication bias for transfusion, the propen-190 The Journal of Thoracic and Cardiovascular Surgsity score was used to match among patients who actually received blood
transfusions (n ¼ 471) those receiving leukodepleted RBCs with those re-
ceiving nonleukodepleted RBCs, and this yielded 147 well-matched pairs
(294 patients; Table 2). The maximal accepted discrepancy between the
scores of patient pairs to be matched was set at1%. Details on propensity
matching are reported in Appendix Tables 1 through 3. The latter patient
subset was the final study sample in which bivariate analysis was used forery c July 2010
TABLE 2. Unmatched and matched transfused samples
Unmatched Matched
Not depleted Depleted P value Not depleted Depleted P value
No. of patients 262 (55.6%) 209 (44.4%) 147 (50%) 147 (50%)
Age (y, mean  SD) 65.5  9.3 66.3  9.4 .372 66.7  8.7 66.3  9.3 .709
Female (no.) 77 (29.4%) 65 (31.1%) .688 50 (34.0%) 40 (27.2%) .127
Body surface area (kg/m2, mean  SD) 1.79  0.15 1.77  0.15 .178 1.78  0.16 1.78  0.15 .876
Diabetes (no.) 78 (29.8%) 69 (33.0%) .340 37 (25.2%) 35 (23.8%) .882
Hypertension (no.) 174 (66.4%) 156 (74.6%) .053 98 (66.7%) 106 (72.1%) .376
Hypercholesterolemia (no.) 105 (40.1%) 90 (43.1%) .513 63 (42.9%) 64 (43.5%) .500
Chronic obstructive pulmonary disease 34 (13.0%) 34 (16%) .313 17 (11.6%) 23 (15.6%) .198
Preoperative glomerular filtration rate
(mL/min, mean  SD)
75.5  21.6 74.7  24.2 .706 75.5  21.8 75.9  25.4 .892
Chronic renal disease (no.) 12 (4.6%) 14 (6.7%) .317 7 (4.8%) 10 (6.8%) .309
Ejection fraction #35% (no.) 54 (20.6%) 29 (13.9%) .059 31 (21.1%) 19 (12.9%) .062
Hematologic disorder (no.) 7 (2.7%) 4 (1.9%) .588 6 (4.1%) 3 (2.0%) .250
History of hemorrhagic gastropathy (no.) 19 (7.3%) 14 (6.7%) .815 9 (6.1%) 10 (6.8%) .500
Preoperative anemia (hemoglobin<12 g/dL, no.) 111 (42.4%) 112 (53.6%) .015 70 (47.6%) 78 (53.1%) .207
Preoperative hemoglobin (g/dL, mean  SD) 12.8  1.8 12.5  1.7 .046 12.6  1.9 12.5  1.6 .770
Use of warfarin (no.) 2 (0.8%) 3 (1.5%) .469 2 (1.4%) 2 (1.4%) .684
Use of ticlopidine (no.) 19 (7.3%) 9 (4.4%) .192 11 (7.5%) 7 (4.8%) .243
Use of clopidogrel (no.) 31 (11.8%) 41 (19.9%) .016 20 (13.6%) 25 (17.2%) .243
Use of aspirin (no.) 116 (44.3%) 99 (48.1%) .415 70 (47.6%) 66 (45.5%) .404
Urgent or emergency setting (no.) 85 (32.4%) 101 (48.3%) .001 51 (34.7%) 63 (42.8%) .278
Resternotomy (no.) 4 (1.5%) 1 (0.5%) .270 2 (1.4%) 0 (0%) .249
No. of distal anastomoses (mean  SD) 2.84  0.82 2.67  0.77 .031 2.78  0.80 2.65  0.70 .220
Pump time (min, mean  SD) 87.8  36.3 95.7  38.4 .022 92.8  40 94.5  38 .717
Aortic crossclamp time (min, mean  SD) 46.1  21.5 50.5  22.5 .032 47.3  22 49.5  21 .397
Indexed pump flow (L/[m2 min], mean  SD) 2.37  0.17 2.38  0.17 .433 2.37  0.19 2.38  0.20 .719
Lowest hemoglobin on pump (g/dL, mean  SD) 8.1  1.14 8.20  1.21 .321 8.0  1.15 8.1  1.20 .285
Lowest oxygen delivery on pump (mean  SD) 274  41 279  44 .433 270  42 275  46 .278
Blood loss in first 24 h (mL, mean  SD) 777  397 792  443 .682 783  379 806  422 .616
Red blood cells transfused (units, mean  SD)
Total 3.9  3.1 4.2  2.7 .448 4.2  3.2 4.2  2.7 .985
In operating room 1.53  1.6 1.84  1.6 .037 1.66  1.5 1.78  1.6 .247
In intensive care unit 2.20  2.5 1.97  2.0 .270 2.39  2.7 2.1  2.0 .174
Total fresh plasma transfused (units, mean  SD) 2.6  3.9 2.6  3.4 .98 2.5  4.1 2.7  3.6 .606
Total platelets transfused (units, mean  SD) 2.7  5.8 2.7  4.2 .97 2.7  6.7 2.7  4.3 .812
Resternotomy for bleeding (no.) 13 (5.0%) 11 (5.3%) .883 7 (4.8%) 7 (4.8%) .607
Respiratory complication (no.) 10 (3.8%) 17 (8.1%) .045 9 (6.1%) 13 (8.8%) .253
Cardiac complication (no.) 24 (9.2%) 30 (14.4%) .079 10 (10.9%) 19 (12.9%) .362
Intra-aortic balloon pump (no.) 26 (9.9%) 43 (20.6%) .001 17 (11.6%) 31 (21.1%) .020
Cerebral complication (no.) 11 (4.2%) 4 (1.9%) .127 5 (3.4%) 2 (1.4%) .224
RIFLE class R or worse (no.) 127 (48.5%) 81 (38.7%) .039 76 (51.7%) 61 (41.5%) .045
Use of continuous venovenous hemofiltration (no.) 17 (6.5%) 15 (7.2%) .768 14 (9.5%) 11 (7.5%) .338
Pneumonia (no.) 12 (4.6%) 22 (10.5%) .048 10 (6.8%) 15 (10.2%) .125
Bloodstream infection (no.) 11 (4.2%) 9 (4.3%) .880 8 (5.4%) 7 (4.8%) .545
Mediastinitis (no.) 9 (3.4%) 4 (1.4%) .317 2 (1.4%) 3 (2.0%) .652
Intensive care unit stay (d, mean  SD) 3.9  5.7 4.5  5.3 .317 4.4  5.7 4.7  5.6 .557
Hospital stay (d, mean  SD) 8.6  6.9 9.9  6.5 .034 9.2  6.7 10.3  6.6 .147
In-hospital mortality (no.) 21 (8.0%) 10 (4.8%) .160 17 (11.6%) 8 (5.4%) .046
RIFLE, Risk, Injury, Failure, Loss of function, End-stage renal disease.
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Moutcome measurement. Finally, multivariable logistic regression analysis
was used to identify predictors of CSA-AKI and in-hospital mortality, forc-
ing the propensity score to enter the models as a covariate to distinguish be-
tween the real effects of transfusion and those of the conditions indicating
transfusion. Because propensity score analysis, although improving speci-
ficity of the results, actually reduces statistical power, outcomes were alsoThe Journal of Thoracic and Caanalyzed with conventional multivariable regression model (backward step-
wise) on the entire cohort of transfused patients (n ¼ 471). Adjustment was
made only for preoperative and intraoperative confounders, and nonleuko-
depleted transfusion was forced as a covariate in the regression model to as-
sess the direct and indirect effects of leukoreduction on outcomes. Data are
expressed as mean  SD for continuous variables and as percentages forrdiovascular Surgery c Volume 140, Number 1 191
FIGURE 1. RIFLE (Risk, Injury, Failure, Loss of function, End-stage re-
nal disease) scoring in matched pairs. Not-D, Nonleukodepleted; D, leuko-
depleted.
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Mcategoric variables. All statistical analyses were performed with SPSS 13.0
(SPSS Inc, an IBM Company, Chicago, Ill).
RESULTS
Study Sample Features
Transfused patient subsets in the 2 study periods
proved inhomogeneous with respect to preoperative and
perioperative features as well as in-hospital process of care
characteristics. Propensity matching allowed analysis of
147 well-matched pairs (Table 2).
Study End Points in Unmatched and Propensity-
Matched Groups
Both incidence of CSA-AKI class R or greater and in-
hospital mortality were higher among unmatched patientsTABLE 3. Logistic regression modeling for cardiac surgery–associated ac
b Odd
Renal dysfunction in transfused patients (n ¼ 471)
Nonleukodepleted transfusions 0.61 1
Hypertension 0.49 1
Intra-aortic balloon pump 0.67 1
Aortic crossclamp time 0.013 1
Transfusion (per unit) 0.13 1
In-hospital mortality among transfused
patients (n ¼ 471)
Female sex 0.97 2
Transfusion (per unit) 0.21 1
Preoperative anemia 0.95 2
Renal dysfunction (n ¼ 147 matched pairs)
Intra-aortic balloon pump 0.764 2
Leukodepleted transfusions 0.493 0
In-hospital mortality (n ¼ 147 matched pairs)
Propensity score for transfusions 0.958 2
Intra-aortic balloon pump 1.704 0
RIFLE class R or worse 2.300 9
RIFLE, Risk, Injury, Failure, Loss of function, End-stage renal disease.
192 The Journal of Thoracic and Cardiovascular Surgwith nonleukodepleted transfusions, who otherwise were
significantly less affected by respiratory complications and
pneumonia. After propensity matching, patients in the non-
leukodepleted group still showed significantly worse out-
comes. Indeed, as reported in Table 2, they had
a significantly higher incidence of CSA-AKI. RIFLE scores
in the 2 groups are reported in Figure 1. Consistently,
in-hospital mortality was higher. Differences in other in-
hospital complications were not significant. The observed
relative risk reductions for the measured outcomes were
nearly 20% for CSA-AKI and 50% for in-hospital death af-
ter the introduction of the leukodepletion program.
Multivariable Regression Modeling for Study End
Points
Multivariable logistic regression analysis for primary end
points is reported in Table 3. In the entire cohort of trans-
fused patients, predictors of in-hospital mortality were fe-
male sex, transfusion, and preoperative anemia; predictors
of CSA-AKI were hypertension, IABP, crossclamp dura-
tion, and transfusion. Because the number of units trans-
fused and the propensity score for transfusion were
collinear variables, the former was not included in the ad-
justed model to avoid redundancy.
With respect to propensity-matched groups, IABP, RI-
FLE scoring, and propensity scoring for transfusion proved
independent predictors of in-hospital mortality. IABP and
nonleukodepleted transfusions emerged as independent pre-
dictors of CSA-AKI.
DISCUSSION
This before-and-after study aimed to evaluate the effects
of the implementation of a universal leukoreductionute kidney injury and in-hospital mortality
s ratio 95% Confidence interval P value
.85 1.23–2.76 .003
.63 1.06–2.50 .025
.95 1.10–3.46 .022
.01 1.004–1.023 .003
.14 1.05–1.23 <.001
.65 1.08–6.5 .033
.23 1.10–1.37 <.001
.6 1.0–6.7 .05
.147 1.128–4.085 .020
.611 0.381–0.979 .040
.606 1930–3851 <.001
.182 0.047–0.798 .030
.970 8.710–50.082 <.001
ery c July 2010
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Mprogram on morbidity and mortality after CABG. Trans-
fused patient subsets in the 2 study periods proved inhomo-
geneous with regard to preoperative and perioperative
features as well as in-hospital process of care characteristics.
Indeed, patients operated on during the latter phase were
sicker and more often in unstable condition preoperatively
and thus more subject to cardiac and respiratory complica-
tions. Propensity-matching data processing allowed analysis
of 147 well-matched pairs, which represented a subset of
transfused patients homogeneous with regard to factors pre-
disposing toward transfusion, thus excluding possible ef-
fects of arbitrariness in transfusional triggers. Main
findings of the analysis were that the introduction of a leukor-
eduction program in a tertiary care cardiac surgery center
yielded (1) similar incidences of major postoperative infec-
tions and of cardiac and respiratory complications, (2) sig-
nificantly reduced incidence of CSA-AKI, and (3) reduced
in-hospital mortality.
Data regarding infectious complications deserve some
consideration. Incidences of surgical site infections and
ventilator-associated pneumonia and bloodstream infections
proved similar in matched pairs, and none of these emerged
as a predictor in regression analysis for death. Such results
are at odds with earlier reports on the benefits of leukoreduc-
tion, yet consistent with more recent experiences and
reviews.2,4,6
The incidence of CSA-AKI, according to a variety of his-
torical definitions, usually ranges from 0.3% to 29.7%.10 In
the overall study sample, a reduction of GFR greater than
50% was detected in as many as 5.3% of the patients,
with a need for renal replacement therapy in 3.3%, with
higher incidences in transfused subsets. The development
of CSA-AKI is associated with increased morbidity and
mortality and resource use. As authoritatively outlined, the
pathophysiology of such a dreaded complication is likely
to involve the following mechanisms, processes, factors,
or pathways: (1) exogenous and endogenous toxins, (2) met-
abolic factors, (3) ischemia–reperfusion, (4) neurohormonal
activation, (5) inflammation, and (6) oxidative stress.11
Transfusion of allogeneic RBCs is increasingly recognized
as a risk factor for adverse outcomes after cardiac surgery,
including the development of CSA-AKI.12 Leukocytes in
transfused blood are associated with several posttransfusion
immunomodulatory effects.13 Although leukocytes are
known to play an important role in the development of acute
kidney injury, the contribution of leukocytes in transfused
blood products has not been fully investigated.14,15
In this series, multivariable regression modeling revealed
that RIFLE class R or higher independently predicted in-
hospital death, consistent with previous studies in the cardiac
surgical setting.16 Regression modeling for CSA-AKI dis-
closed the predictive roles of low output, severe ischemia,
and cardiogenic shock conditions necessitating IABP place-
ment and the protective effects of leukoreduced transfusion.The Journal of Thoracic and CaAlthough the former result is intuitively explained in the
view of a more compromised hemodynamic state causing
prerenal failure, the mechanism underlying the latter evi-
dence, namely the pathophysiology of CSA-AKI, is complex
and multifactorial.11 Cardiopulmonary bypass–related
ischemia–reperfusion injury initiates changes in vascular
endothelial cells, tubular epithelial cells, and leukocytes
that result in the loss of immune system homeostasis in the
kidney. The ensuing inflammation leads to kidney parenchy-
mal cell death and in severe cases to CSA-AKI.17,18 There is
a growing body of basic science evidence demonstrating that
whatever the prime etiology, the effectors of acute renal
damage include immune mediators. On the other hand, in
the clinical setting, it has been widely demonstrated that
leukoreduction may improve outcomes.19-22 A recent
review of the various types of leukocyte-depleting filtration
strategies in cardiac surgery has further elucidated the inter-
actions between leukocyte activation and renal dysfunction.3
In particular, the randomized, controlled trial by Tang and
coworkers19 focusing on sensitive indicators such as urinary
microalbumin and urinary retinol binding protein disclosed
a significantly greater degree of injury to renal tubules and
glomeruli in patients who did not have leukocyte depletion.19
In-hospital mortality in the overall patients subset was
significantly higher among transfused patients than among
their nontransfused counterparts (0.2% vs 6.6%), in accor-
dance with other major series.1,12 To evaluate the effects
on hospital outcomes of leukocytes in blood products
administered during cardiac surgery, several authoritative
studies are available.2,4,20-23 In most of them,
leukoreduction was associated with lower mortality.
Consistently, the introduction of a universal leukoreduction
program was associated with a significant reduction in
fatality rate in matched pairs at our institution. The exact
mechanism associated with such decreased mortality has
not yet been unraveled. In this series, as shown by
multivariable modeling, the reduction in mortality was
directly related to the preservation of renal function,
impairment of which is known as one of the strongest
independent predictors of death after CABG.10,11 The
protective effect exerted by IABP support was consistent
with major series.24 Finally, it is noteworthy that the propen-
sity score for the likelihood of receiving transfusion appeared
as another independent predictor of in-hospital mortality.
Data for hospital outcomes from the propensity-matched
analysis confirmed those derived from multivariable regres-
sion models on the overall cohort of transfused patients and
were consistent with those reported in most series.
Study Overview
Several study limitations should be considered for a thor-
ough data interpretation. First, the single-center setting,
although a guarantee of uniform processes of care, especially
in terms of transfusion triggers, closely reflects the influencerdiovascular Surgery c Volume 140, Number 1 193
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population that may have led to results not readily transfer-
able to other patient populations. Second, before-and-after
study designs are usually susceptible to selection and infor-
mation biases. Indeed, the lack of blinding and the use of co-
horts from different periods rather than prospective
randomization do not prevent uneven distribution of patients
with different demographic characteristics and risk factors
and also overlook possible differences in the level of care
with time. In this study, however, the inclusion of all consec-
utive patients admitted for CABG, prospective data mining
through the hospital’s quality assurance program, and cor-
rectness of statistical tools in balancing for confounders
helped to make results objective and transferable.
Finally, no evaluation was performed of possible dose de-
pendence of nonleukodepleted versus leukodepleted RBCs’
effect on CSA-AKI and mortality. Patients with the highest
propensity scores for transfusion, that is, those entering
in matched comparison, were also those with the greatest
numbers of units received, and this hampered any possible
dose-dependence assessment.CONCLUSIONS
To the best of our knowledge, this is the first time that the
already reported lower mortality with leukodepleted transfu-
sions has been demonstrated to be associated with a lower
rate of CSA-AKI. The pathophysiologic mechanisms lead-
ing to these potential health benefits have not been eluci-
dated. Further large, prospective clinical trials are
warranted to demonstrate the efficacy of a leukoreduction
strategy in the cardiac surgical setting. Cost-effectiveness
of a universal application of prestorage leukodepletion needs
further evaluation. Future clinical trials should be under-
taken to verify in a prospective, randomized design the ben-
efits of allogeneic RBC leukodepletion demonstrated in this
study in terms of hospital outcomes, and in particular to
elucidate the relationship between reduced mortality and
decreased incidence of renal failure.
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APPENDIX TABLE 1. Variables used for propensity scoring
Transfusion
No Yes
Sex 28.529 29.787
Body surface area 90.114 87.062
Kidney disease 7.077 7.515
Preoperative estimated glomerular filtration rate 0.220 0.210
Diabetes 0.490 0.421
Continuous venovenous hemofiltration 1.479 2.572
First-day drainages 0.008 0.009
Hematologic disorders 1.560 1.481
Use of ticlopidine 2.762 3.578
Surgical indication criteria 1.418 1.054
No. of bypass grafts 3.048 3.255
Low preoperative ejection fraction 1.845 1.961
Reoperation for infection 4.860 4.832
Reoperation for excessive bleeding 1.931 3.722
Intra-aortic balloon pump 1.193 2.044
Cardiopulmonary bypass time 0.054 0.064
Oxygen delivery 0.136 0.124
Preoperative anemia 4.600 6.163
Respiratory complications 3.770 3.978
Cardiac complications 0.992 1.618
Cerebral complications 2.316 1.681
Constant 141.527 136.399
Fisher’s linear discriminant functions.
APPENDIX TABLE 2. Test for risk score equality in matched pairs: Discriminant scores
N Mean SD SE
95% Confidence
interval for mean
Lower bound Upper bound Minimum Maximum
Not depleted 147 0.9760920 1.10574557 0.09120036 0.7958485 1.1563354 1.38638 5.56434
Depleted 147 0.9745711 1.10126990 0.09083121 0.7950572 1.1540850 1.36490 5.39681
Total 294 0.9753315 1.10162554 0.06424811 0.8488853 1.1017778 1.38638 5.56434
APPENDIX TABLE 3. Test for risk score equality in matched pairs: Analysis of variance discriminant scores
Sum of squares df Mean square F P value
Between groups 0.000 1 0.000 0.000 .991
Within groups 355.578 292 1.218
Total 355.579 293
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